Published in Eur J Cancer on March 11, 2009
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res (2010) 2.44
Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89
A gist of gastrointestinal stromal tumors: A review. World J Gastrointest Oncol (2013) 1.72
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol (2014) 1.67
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat (2010) 1.47
Gastrointestinal stromal tumors. Int J Colorectal Dis (2011) 1.39
Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res (2009) 1.38
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer (2009) 1.33
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res (2012) 1.25
PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST. CPT Pharmacometrics Syst Pharmacol (2013) 1.12
Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol (2010) 1.08
Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer (2010) 1.08
Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience. BMC Cancer (2013) 1.07
Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol (2014) 1.00
GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). Cancer Chemother Pharmacol (2014) 0.99
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer (2011) 0.96
PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST. CPT Pharmacometrics Syst Pharmacol (2013) 0.93
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. Biologics (2010) 0.93
Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors. Appl Clin Genet (2010) 0.91
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med (2011) 0.91
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer (2015) 0.90
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations. PLoS One (2013) 0.88
Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int J Cancer (2013) 0.87
Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution. ISRN Oncol (2011) 0.87
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer (2014) 0.86
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. Invest New Drugs (2010) 0.86
Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor. J Transl Med (2014) 0.85
Gastrointestinal stromal tumor: a bridge between bench and bedside. Gastric Cancer (2010) 0.85
Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious. J Gastrointest Oncol (2016) 0.84
Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan. World J Surg Oncol (2012) 0.84
Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol Oncol Clin North Am (2013) 0.84
Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. BMC Cancer (2014) 0.84
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer (2014) 0.83
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions. Drugs (2015) 0.83
Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy. Mol Ther (2013) 0.82
Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria. Wien Med Wochenschr (2013) 0.82
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. Leuk Lymphoma (2011) 0.82
Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. Cancer Res Treat (2016) 0.82
Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials. PLoS One (2011) 0.81
Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction. J Invest Dermatol (2014) 0.81
Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy. J Gastrointest Cancer (2014) 0.81
New drugs and combinations for the treatment of soft-tissue sarcoma: a review. Cancer Manag Res (2012) 0.80
Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib. J Transl Med (2012) 0.80
Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors. Ther Adv Med Oncol (2012) 0.79
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs (2009) 0.79
Abdominal wall recurrence of a gastrointestinal stromal tumor: case report. Springerplus (2015) 0.79
Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. Br J Clin Pharmacol (2015) 0.78
Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours. Curr Oncol (2014) 0.78
Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Invest New Drugs (2010) 0.78
Clinical and therapeutic considerations of GIST. J Med Life (2014) 0.78
Combining radiotherapy with sunitinib: lessons (to be) learned. Angiogenesis (2015) 0.78
Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. Case Rep Oncol (2012) 0.78
Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor. Jpn J Clin Oncol (2015) 0.77
PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor. CPT Pharmacometrics Syst Pharmacol (2016) 0.77
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. Invest New Drugs (2013) 0.77
Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. Clin Sarcoma Res (2014) 0.77
Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis. BMC Cancer (2016) 0.77
Pancreatic GIST in a Patient with Limited Stage Small Cell Lung Cancer: A Case Report and Review of Published Cases. Case Rep Oncol Med (2016) 0.76
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. Clin Pharmacokinet (2016) 0.76
A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemother Pharmacol (2011) 0.76
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget (2015) 0.76
Gastrointestinal stromal tumors: Recommendations on diagnosis, therapy and follow-up care in Austria. Wien Klin Wochenschr (2009) 0.76
Targeting gastrointestinal stromal tumors: the role of regorafenib. Onco Targets Ther (2016) 0.75
Accomplishments in 2008 in the management of gastrointestinal stromal tumors. Gastrointest Cancer Res (2009) 0.75
Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression. Oncologist (2013) 0.75
Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches. Oncol Ther (2016) 0.75
UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST). Clin Sarcoma Res (2017) 0.75
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer (2016) 0.75
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence. Clin Pharmacokinet (2015) 0.75
Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. Oncol Lett (2014) 0.75
Indian Council of Medical Research consensus document for the management of gastrointestinal stromal tumors. Indian J Med Paediatr Oncol (2014) 0.75
Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives. Onco Targets Ther (2016) 0.75
Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther (2016) 0.75
Succinate dehydrogenase-deficient gastrointestinal stromal tumors. World J Gastroenterol (2015) 0.75
Complete response to second-line chemotherapy with sunitinib of a gastrointestinal stromal tumor: A case report. Mol Clin Oncol (2017) 0.75
Recent advances in managing gastrointestinal stromal tumor. F1000Res (2017) 0.75
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol (2017) 0.75
[Gastrointestinal stromal tumors: recommendations for diagnosis, treatment and aftercare in Austria]. Wien Med Wochenschr (2009) 0.75
Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary: identification of the best benefited patients. Eur J Nucl Med Mol Imaging (2016) 0.75
[Treatment of extensive disease]. Wien Med Wochenschr (2009) 0.75
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med (2001) 7.88
Role of the conserved AAUAAA sequence: four AAUAAA point mutants prevent messenger RNA 3' end formation. Science (1984) 7.35
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res (2001) 5.40
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol (2005) 5.27
Sequence of the OXA2 beta-lactamase: comparison with other penicillin-reactive enzymes. FEBS Lett (1985) 3.69
Comparison of non-mydriatic retinal photography with ophthalmoscopy in 2159 patients: mobile retinal camera study. BMJ (1990) 3.65
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene (2001) 3.36
Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood (1998) 2.93
Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol (2008) 2.85
Isolation and chromosomal localization of cDNAs encoding a novel human lymphocyte cell surface molecule, LAM-1. Homology with the mouse lymphocyte homing receptor and other human adhesion proteins. J Exp Med (1989) 2.67
Photosynthesis of Grass Species Differing in Carbon Dioxide Fixation Pathways : VI. DIFFERENTIAL EFFECTS OF TEMPERATURE AND LIGHT INTENSITY ON PHOTORESPIRATION IN C(3), C(4), AND INTERMEDIATE SPECIES. Plant Physiol (1980) 2.62
The AAUAAA sequence is required both for cleavage and for polyadenylation of simian virus 40 pre-mRNA in vitro. Mol Cell Biol (1986) 2.62
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Association of p300 and CBP with simian virus 40 large T antigen. Mol Cell Biol (1996) 2.40
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg (1995) 2.28
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol (2005) 2.24
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer (2003) 2.20
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol (2000) 2.20
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol (2007) 2.15
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol (2004) 2.15
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol (2008) 2.10
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol (2004) 2.08
A multicenter study of treatment of primary CNS lymphoma. Neurology (2002) 2.04
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2001) 1.99
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol (2014) 1.97
Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer (1998) 1.96
Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol (2003) 1.96
Sequence and location of the poly C tract in aphtho- and cardiovirus RNA. Nucleic Acids Res (1979) 1.95
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene (2007) 1.84
Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol (2004) 1.80
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer (2001) 1.78
Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg (1999) 1.76
Management of soft-tissue sarcomas: an overview and update. Lancet Oncol (2000) 1.76
Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg (2001) 1.73
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer (2003) 1.70
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol (2003) 1.68
Added value of molecular targeted agents in oncology. Ann Oncol (2011) 1.65
Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol (2008) 1.62
Molecular cloning of two Pseudomonas flagellin genes and basal body structural genes. Microbiology (1994) 1.62
Differential regulation of lambda pL and pR promoters by a cI repressor in a broad-host-range thermoregulated plasmid marker system. Appl Environ Microbiol (1989) 1.62
Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer (1999) 1.61
Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 1.61
Products of in vitro cleavage and polyadenylation of simian virus 40 late pre-mRNAs. Mol Cell Biol (1987) 1.61
Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol (2005) 1.59
Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol (2010) 1.59
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol (2010) 1.58
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer (2008) 1.57
Rectal mucosal plasma cells in inflammatory bowel disease. Gut (1983) 1.56
The bacterial flagellin gene as a biomarker for detection, population genetics and epidemiological analysis. Microbiology (1997) 1.55
The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol (2012) 1.53
Body mass index, waist circumference, waist-hip ratio, and glucose intolerance in Chinese and Europid adults in Newcastle, UK. J Epidemiol Community Health (1997) 1.51
Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol (2005) 1.51
Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism. Nat Genet (1998) 1.50
Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol (2007) 1.47
Malignant epithelioid angiomyolipoma ('sarcoma ex angiomyolipoma') of the kidney: a case report and review of the literature. Am J Surg Pathol (2001) 1.47
Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol (2007) 1.45
Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res (1996) 1.45
Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol (2004) 1.42
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol (2011) 1.40
Cervical cytology in pregnancy. Br Med J (1969) 1.40
Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest (1997) 1.39
Scalp laceration repair without prior hair removal. Am J Emerg Med (1988) 1.38
Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer (2001) 1.36
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (2011) 1.36
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol (2012) 1.35
The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today (1997) 1.34
Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol (2009) 1.34
A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer (2010) 1.33
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol (2009) 1.31
Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer (2012) 1.30
Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol (1996) 1.30
Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol (2009) 1.30
Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol (2013) 1.30
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol (2011) 1.29
Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol (1999) 1.29
Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol (1996) 1.27
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer (2011) 1.27
The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2007) 1.27
Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med (1996) 1.27
Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol (2008) 1.24
Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol (2011) 1.24
Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol (1998) 1.23
Electrophysiological studies in familial spastic paraplegia. J Neurol Neurosurg Psychiatry (1977) 1.23
Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol (2010) 1.22